Calliditas Therapeutics AB Income Statement

Ask AI

Financial Statements

In millions of SEK, except per-share amounts

	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Net sales
Cost of sales
Gross profit
Research and development expenses
Administrative and selling expenses
Marketing and selling expenses
Administrative expenses
Other operating income
Other operating expenses
Operating loss
Financial income
Financial expenses
Loss before income tax
Income tax expense
Loss for the year
Attributable to:
Equity holders of the Parent Company
Non-controlling interests
Loss per share
Before dilution to ordinary equity holders of the Parent Company
After dilution to ordinary equity holders of the Parent Company

Comments